The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Research Report 2025
Synopsis
Phosphodiesterase type 5 inhibitor (PDE5 inhibitor) is a drug used to block degradation of cgmp-specific phosphodiesterase type 5 (PDE5) loop GMP in smooth muscle cell lining supplying blood vessels to various tissues.These drugs dilate the cavernous penis, promote erections with sexual stimulation, and are used to treat erectile dysfunction (ED).Sildenafil is the first effective oral therapy for ED.Because PDE5 is also present in the wall of the smooth muscle arterioles of the inner lung, sildenafil and tadalafil dilate these vessels and are FDA approved for the treatment of pulmonary hypertension.
The global Phosphodiesterase Type 5 (PDE5) Inhibitor market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Phosphodiesterase Type 5 (PDE5) Inhibitor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Phosphodiesterase Type 5 (PDE5) Inhibitor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Phosphodiesterase Type 5 (PDE5) Inhibitor in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Phosphodiesterase Type 5 (PDE5) Inhibitor include Eli Lilly, Pfizer, Bayer, Novartis AG, Merck, GlaxoSmithKline plc, Roche, AstraZeneca and BaiYunShan General Factory, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Phosphodiesterase Type 5 (PDE5) Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Phosphodiesterase Type 5 (PDE5) Inhibitor.
Report Scope
The Phosphodiesterase Type 5 (PDE5) Inhibitor market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Phosphodiesterase Type 5 (PDE5) Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Phosphodiesterase Type 5 (PDE5) Inhibitor companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly
Pfizer
Bayer
Novartis AG
Merck
GlaxoSmithKline plc
Roche
AstraZeneca
BaiYunShan General Factory
SK Chemicals
Teva Pharma
Dong-A ST
Metuchen Pharma
Seoul Pharma
Vectura Group
Segment by Type
Sildenafil
Tadalafil
Avanafil
Vardenafil
Segment by Application
Hospital
Retail Pharmacy
Online Pharmacies
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Phosphodiesterase Type 5 (PDE5) Inhibitor companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Phosphodiesterase type 5 inhibitor (PDE5 inhibitor) is a drug used to block degradation of cgmp-specific phosphodiesterase type 5 (PDE5) loop GMP in smooth muscle cell lining supplying blood vessels to various tissues.These drugs dilate the cavernous penis, promote erections with sexual stimulation, and are used to treat erectile dysfunction (ED).Sildenafil is the first effective oral therapy for ED.Because PDE5 is also present in the wall of the smooth muscle arterioles of the inner lung, sildenafil and tadalafil dilate these vessels and are FDA approved for the treatment of pulmonary hypertension.
The global Phosphodiesterase Type 5 (PDE5) Inhibitor market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Phosphodiesterase Type 5 (PDE5) Inhibitor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Phosphodiesterase Type 5 (PDE5) Inhibitor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Phosphodiesterase Type 5 (PDE5) Inhibitor in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Phosphodiesterase Type 5 (PDE5) Inhibitor include Eli Lilly, Pfizer, Bayer, Novartis AG, Merck, GlaxoSmithKline plc, Roche, AstraZeneca and BaiYunShan General Factory, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Phosphodiesterase Type 5 (PDE5) Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Phosphodiesterase Type 5 (PDE5) Inhibitor.
Report Scope
The Phosphodiesterase Type 5 (PDE5) Inhibitor market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Phosphodiesterase Type 5 (PDE5) Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Phosphodiesterase Type 5 (PDE5) Inhibitor companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly
Pfizer
Bayer
Novartis AG
Merck
GlaxoSmithKline plc
Roche
AstraZeneca
BaiYunShan General Factory
SK Chemicals
Teva Pharma
Dong-A ST
Metuchen Pharma
Seoul Pharma
Vectura Group
Segment by Type
Sildenafil
Tadalafil
Avanafil
Vardenafil
Segment by Application
Hospital
Retail Pharmacy
Online Pharmacies
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Phosphodiesterase Type 5 (PDE5) Inhibitor companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Sildenafil
1.2.3 Tadalafil
1.2.4 Avanafil
1.2.5 Vardenafil
1.3 Market by Application
1.3.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacies
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Perspective (2019-2030)
2.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Growth Trends by Region
2.2.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Historic Market Size by Region (2019-2024)
2.2.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Forecasted Market Size by Region (2025-2030)
2.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Dynamics
2.3.1 Phosphodiesterase Type 5 (PDE5) Inhibitor Industry Trends
2.3.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Drivers
2.3.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Challenges
2.3.4 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Phosphodiesterase Type 5 (PDE5) Inhibitor Players by Revenue
3.1.1 Global Top Phosphodiesterase Type 5 (PDE5) Inhibitor Players by Revenue (2019-2024)
3.1.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Players (2019-2024)
3.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue
3.4 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Concentration Ratio
3.4.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue in 2023
3.5 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players Head office and Area Served
3.6 Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Product Solution and Service
3.7 Date of Enter into Phosphodiesterase Type 5 (PDE5) Inhibitor Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Phosphodiesterase Type 5 (PDE5) Inhibitor Breakdown Data by Type
4.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Historic Market Size by Type (2019-2024)
4.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Forecasted Market Size by Type (2025-2030)
5 Phosphodiesterase Type 5 (PDE5) Inhibitor Breakdown Data by Application
5.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Historic Market Size by Application (2019-2024)
5.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2019-2030)
6.2 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2019-2024)
6.4 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2019-2030)
7.2 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2019-2024)
7.4 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2019-2030)
8.2 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Region (2019-2024)
8.4 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2019-2030)
9.2 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2019-2024)
9.4 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2019-2030)
10.2 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2019-2024)
10.4 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Eli Lilly
11.1.1 Eli Lilly Company Detail
11.1.2 Eli Lilly Business Overview
11.1.3 Eli Lilly Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.1.4 Eli Lilly Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2019-2024)
11.1.5 Eli Lilly Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.2.4 Pfizer Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2019-2024)
11.2.5 Pfizer Recent Development
11.3 Bayer
11.3.1 Bayer Company Detail
11.3.2 Bayer Business Overview
11.3.3 Bayer Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.3.4 Bayer Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2019-2024)
11.3.5 Bayer Recent Development
11.4 Novartis AG
11.4.1 Novartis AG Company Detail
11.4.2 Novartis AG Business Overview
11.4.3 Novartis AG Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.4.4 Novartis AG Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2019-2024)
11.4.5 Novartis AG Recent Development
11.5 Merck
11.5.1 Merck Company Detail
11.5.2 Merck Business Overview
11.5.3 Merck Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.5.4 Merck Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2019-2024)
11.5.5 Merck Recent Development
11.6 GlaxoSmithKline plc
11.6.1 GlaxoSmithKline plc Company Detail
11.6.2 GlaxoSmithKline plc Business Overview
11.6.3 GlaxoSmithKline plc Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.6.4 GlaxoSmithKline plc Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2019-2024)
11.6.5 GlaxoSmithKline plc Recent Development
11.7 Roche
11.7.1 Roche Company Detail
11.7.2 Roche Business Overview
11.7.3 Roche Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.7.4 Roche Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2019-2024)
11.7.5 Roche Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Detail
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.8.4 AstraZeneca Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2019-2024)
11.8.5 AstraZeneca Recent Development
11.9 BaiYunShan General Factory
11.9.1 BaiYunShan General Factory Company Detail
11.9.2 BaiYunShan General Factory Business Overview
11.9.3 BaiYunShan General Factory Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.9.4 BaiYunShan General Factory Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2019-2024)
11.9.5 BaiYunShan General Factory Recent Development
11.10 SK Chemicals
11.10.1 SK Chemicals Company Detail
11.10.2 SK Chemicals Business Overview
11.10.3 SK Chemicals Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.10.4 SK Chemicals Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2019-2024)
11.10.5 SK Chemicals Recent Development
11.11 Teva Pharma
11.11.1 Teva Pharma Company Detail
11.11.2 Teva Pharma Business Overview
11.11.3 Teva Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.11.4 Teva Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2019-2024)
11.11.5 Teva Pharma Recent Development
11.12 Dong-A ST
11.12.1 Dong-A ST Company Detail
11.12.2 Dong-A ST Business Overview
11.12.3 Dong-A ST Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.12.4 Dong-A ST Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2019-2024)
11.12.5 Dong-A ST Recent Development
11.13 Metuchen Pharma
11.13.1 Metuchen Pharma Company Detail
11.13.2 Metuchen Pharma Business Overview
11.13.3 Metuchen Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.13.4 Metuchen Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2019-2024)
11.13.5 Metuchen Pharma Recent Development
11.14 Seoul Pharma
11.14.1 Seoul Pharma Company Detail
11.14.2 Seoul Pharma Business Overview
11.14.3 Seoul Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.14.4 Seoul Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2019-2024)
11.14.5 Seoul Pharma Recent Development
11.15 Vectura Group
11.15.1 Vectura Group Company Detail
11.15.2 Vectura Group Business Overview
11.15.3 Vectura Group Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.15.4 Vectura Group Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2019-2024)
11.15.5 Vectura Group Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
